Miranda Schmalfuhs
Miranda Schmalfuhs is the associate group social media editor of Pharmaceutical Executive, Pharmaceutical Commerce, and Applied Clinical Trials and can be reached at mschmalfuhs@mjhlifesciences.com.
Articles
The Broader Societal Implications of Maternal Health Issues
July 30th 2024In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses the societal implications of maternal health issues both short and long term.
Addressing OUD Treatment Gaps & Improving Patient Outcomes
July 23rd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses how the findings from this study contribute to addressing treatment gaps and improving patient outcomes for those struggling with fentanyl dependence, ensuring broader patient access to BRIXADI®, and more.
Braeburn on BRIXADI® Research and Addressing Fentanyl's Impact on OUD
July 22nd 2024In this part of his Pharmaceutical Executive video interview, Joshua M. Cohen, MD, MPH, FAHS, Chief Medical Officer, Braeburn discusses data from the Phase III trial recently published in JAMA and how confident they are in the generalizability of these findings to a real-world treatment setting.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
